

Resolution



of the Federal Joint Committee (G-BA) on an Amendment of the Pharmaceuticals Directive (AM-RL): Annex XII – Benefit Assessment of Medicinal Products with New Active Ingredients According to Section 35a SGB V – Olaratumab (Repeal of the Resolution of 18 May 2017)

of 16 January 2020

At its session on 16 January 2020, the Federal Joint Committee (G-BA) resolved to amend the Directive on the Prescription of Medicinal Products in SHI-accredited Medical Care (Pharmaceuticals Directive, AM-RL) in the version dated 18 December 2008 / 22 January 2009 (Federal Gazette, BAnz. No. 49a of 31 March 2009), as last amended on DD Month YYYY (Federal Gazette, BAnz AT DD MM YYYY Bx), as follows:

- I. The findings regarding the benefit assessment of the active ingredient olaratumab in Annex XII to the AM-RL, as amended by the resolution of 18 May 2017 are hereby repealed.**

- II. The resolution will enter into force with effect from the day of its publication on the internet on the website of the G-BA on 16 January 2020.**

The justification to this resolution will be published on the website of the G-BA at www.g-ba.de.

Berlin, 16 January 2020

Federal Joint Committee
in accordance with Section 91 SGB V
The Chair

Prof. Hecken